Global Drug Repositioning Competitive Landscape Professional Research Report 2024
Research Summary
Drug repositioning, also known as drug repurposing, is the process of identifying new therapeutic uses for existing drugs that were originally developed for different purposes. Rather than starting from scratch to discover and develop a new drug, drug repositioning involves investigating the potential benefits of established drugs in treating different diseases or conditions. This approach leverages existing safety and efficacy data, expediting the development timeline and potentially reducing costs. Drug repositioning involves a combination of computational analyses, laboratory experiments, and clinical studies to explore the potential of existing compounds in addressing unmet medical needs or expanding their applications beyond their initial intended uses. This strategy has gained prominence as a promising way to bring new treatments to patients more efficiently and with a higher probability of success.
According to DIResearch's in-depth investigation and research, the global Drug Repositioning market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.
The major global manufacturers of Drug Repositioning include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, Bausch Health, GSK, Glenmark, ChemRar Group, Fujifilm, Dr. Reddy, R-Pharma etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Drug Repositioning. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Drug Repositioning market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Drug Repositioning market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Drug Repositioning industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Drug Repositioning Include:
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
Glenmark
ChemRar Group
Fujifilm
Dr. Reddy
R-Pharma
Drug Repositioning Product Segment Include:
Generic Drugs
Clinical Trial Failed Drugs
Drug Repositioning Product Application Include:
Cardiovascular Diseases
Mental Illness
Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Drug Repositioning Industry PESTEL Analysis
Chapter 3: Global Drug Repositioning Industry Porter’s Five Forces Analysis
Chapter 4: Global Drug Repositioning Major Regional Market Size and Forecast Analysis
Chapter 5: Global Drug Repositioning Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Drug Repositioning Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Drug Repositioning Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources